Psychedelic Weekly Headlines | July 22nd

July 22, 2022
Headlines

Helping investors discover, understand, and stay up-to-date on investment opportunities within the Psychedelic industry.


Markets

Performance of psychedelic public companies this past week.


Company News

Field Trip Health ($FTRP) announced the first successful dosings in their Phase I clinical study of their novel psychedelic molecule, FT-104. The study is focused on the safety, tolerability, pharmacokinetics, and pharmacodynamic effects of FT-104 over a range of doses. Press Release

Wellbeing Digital Sciences ($MEDI $KONEF) announced that their wholly owned subsidiary, KGK Sciences, entered into a research services agreement for a Phase II clinical trial with Halucenex Life Sciences, a psychedelic subsidiary of Creso Pharma. Press Release

Awakn Life Sciences ($AWKN | $AWKNF) announced that the National Institute for Health and Care Research, has approved grant funding for 66% of the costs of Awakn's Phase III clinical trial focused on ketamine-assisted therapy as a potential treatment of Alcohol Use Disorder. Press Release

PharmaTher Holdings ($PHRM | $PHRRF) has been provided a Notice of Allowance for their patent application which includes claims intended to cover ketamine as a potential treatment of Parkinson’s Disease and motor disorders.Press Release

Mydecine Innovations Group ($MYCO | $MYCOF) successfully synthesized multiple short-acting MDMA analogs and applied for patent coverage of their MYCO-006 family of novel MDMA analogs. The analogs have been specifically designed by Mydecine to have a shorter half life than traditional MDMA. Press Release

HAVN Life Sciences ($HAVN | $HAVLF) announced that Alpha Blue Ocean is supporting HAVN's growth with a CAD$‎‎9M ‎‎financing arrangement. HAVN Life intends to use the proceeds to further advance their standardized extraction of psychoactive compounds and the development of natural health products.Press Release

Lobe Sciences ($LOBE | $LOBEF) filed a provisional patent for the preparation and use of their proprietary and stable psilocin related compounds, further strengthening their intellectual property portfolio. Press Release

COMPASS Pathways ($CMPS) appointed Kabir Nath as Chief Executive Officer to accelerate patient access to evidence-based innovation in mental health care. Kabir Nath brings decades of experience in the health care industry to his new role. Press Release

Psyched Wellness ($PSYC | $PSYCF) announced that their proprietary Amanita Muscaria Extract, AME-1, is now available for preorder in the USA. Studies on AME-1 indicate that it has a calming effect while also having a neuroprotective effect at the cellular level. Press Release


Media

Scientific American: Restrictions on Psilocybin Are Easing as Research Ramps Up

Forbes: IMC Fund To Raise $20 Million In Support Of Indigenous-Led ‘Psychedelic’ Projects

Fox: Psychedelic Decriminalization Makes Colorado Ballot

Bloomberg: Psychedelics Business Moves to Mainstream

Leafie: The Rise Of Non-Hallucinogenic Psychedelics


Be the first to see new company features, exclusive interviews and breaking news in the psychedelic markets. Subscribe now.

Always do your own research and make your own investment decisions. This is not a solicitation to purchase or sell securities. Psychedelic Finance is not a registered investment advisor and does not purport to provide investment advice, whether implied or otherwise. Psychedelic Finance does not independently verify the accuracy or the truth of the statements or representations made by issuers. This message is meant for information and educational purposes only and Psychedelic Finance does not intend for this information to be used to inform an investment decision.